64 related articles for article (PubMed ID: 29502139)
1. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer.
Yamada S; Fujii T; Yokoyama Y; Kawashima H; Maeda O; Suzuki K; Okada T; Ono E; Yamaguchi J; Takano N; Takami H; Hayashi M; Niwa Y; Hirooka Y; Ito Y; Naganawa S; Ando Y; Nagino M; Goto H; Kodera Y
Cancer Chemother Pharmacol; 2018 May; 81(5):815-821. PubMed ID: 29502139
[TBL] [Abstract][Full Text] [Related]
2. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial.
Ko AH; Murphy PB; Peyton JD; Shipley DL; Al-Hazzouri A; Rodriguez FA; Womack MS; Xiong HQ; Waterhouse DM; Tempero MA; Guo S; Lane CM; Earwood C; DeBusk LM; Bendell JC
Oncologist; 2017 Dec; 22(12):1427-e129. PubMed ID: 28935773
[TBL] [Abstract][Full Text] [Related]
3. Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study.
Ueno M; Morinaga S; Hashimoto Y; Umemoto K; Sasahira N; Saiura A; Seyama Y; Honda G; Ioka T; Takahashi H; Miyamoto A; Nakamori S; Unno M; Takadate T; Mizuno N; Shimizu Y; Ueno H; Sugiyama M; Fukutomi A; Shimizu S; Okusaka T; Furuse J
Pancreas; 2021 Jan; 50(1):83-88. PubMed ID: 33370027
[TBL] [Abstract][Full Text] [Related]
4. Combination of gemcitabine, nab-paclitaxel, and S-1(GAS) as the first-line treatment for patients with locally advanced or advanced pancreatic ductal adenocarcinoma: study protocol for an open-label, single-arm phase I study.
Chang C; Li X; Cao D
BMC Cancer; 2021 May; 21(1):545. PubMed ID: 33985455
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer with arterial contact: Results from a phase II trial.
Uemura K; Kondo N; Sudo T; Sumiyoshi T; Shintakuya R; Okada K; Baba K; Harada T; Murakami Y; Takahashi S
J Hepatobiliary Pancreat Sci; 2024 May; 31(5):351-362. PubMed ID: 38156372
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical trial.
Zhang D; Benedikt Westphalen C; Quante M; Waldschmidt DT; Held S; Kütting F; Dorman K; Heinrich K; Weiss L; Boukovala M; Haas M; Boeck S; Heinemann V; Probst V
Eur J Cancer; 2024 Apr; 201():113926. PubMed ID: 38401449
[TBL] [Abstract][Full Text] [Related]
7. MR-Guided Radiation Therapy With Concurrent Gemcitabine/Nab-Paclitaxel Chemotherapy in Inoperable Pancreatic Cancer: A TITE-CRM Phase I Trial.
Kim H; Olsen JR; Green OL; Chin RI; Hawkins WG; Fields RC; Hammill C; Doyle MB; Chapman W; Suresh R; Tan B; Pedersen K; Jansen B; DeWees TA; Lu E; Henke LE; Badiyan S; Parikh PJ; Roach MC; Wang-Gillam A; Lim KH
Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):214-223. PubMed ID: 35878713
[TBL] [Abstract][Full Text] [Related]
8. Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma.
Grierson PM; Tan B; Pedersen KS; Park H; Suresh R; Amin MA; Trikalinos NA; Knoerzer D; Kreider B; Reddy A; Liu J; Der CJ; Wang-Gillam A; Lim KH
Oncologist; 2023 Feb; 28(2):e115-e123. PubMed ID: 36427020
[TBL] [Abstract][Full Text] [Related]
9. Protocol of the IntenSify-Trial: An open-label phase I trial of the CYP3A inhibitor cobicistat and the cytostatics gemcitabine and nab-paclitaxel in patients with advanced stage or metastatic pancreatic ductal adenocarcinoma to evaluate the combination's pharmacokinetics, safety, and efficacy.
Hohmann N; Sprick MR; Pohl M; Ahmed A; Burhenne J; Kirchner M; Le Cornet L; Kratzmann M; Hajda J; Stenzinger A; Steindorf K; Delorme S; Schlemmer HP; Riethdorf S; van Schaik R; Pantel K; Siveke J; Seufferlein T; Jäger D; Haefeli WE; Trumpp A; Springfeld C
Clin Transl Sci; 2023 Dec; 16(12):2483-2493. PubMed ID: 37920921
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004).
Toyoda M; Ajiki T; Fujiwara Y; Nagano H; Kobayashi S; Sakai D; Hatano E; Kanai M; Nakamori S; Miyamoto A; Tsuji A; Kaihara S; Ikoma H; Takemura S; Toyokawa H; Terajima H; Morita S; Ioka T
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1295-301. PubMed ID: 24614947
[TBL] [Abstract][Full Text] [Related]
11. A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer.
Arnoletti JP; Frolov A; Eloubeidi M; Keene K; Posey J; Wood T; Greeno E; Jhala N; Varadarajulu S; Russo S; Christein J; Oster R; Buchsbaum DJ; Vickers SM
Cancer Chemother Pharmacol; 2011 Apr; 67(4):891-7. PubMed ID: 20589377
[TBL] [Abstract][Full Text] [Related]
12. Translational PK-PD/TD modeling of antitumor effects and peripheral neuropathy in gemcitabine and nab-paclitaxel chemotherapy from xenograft mice to patients for optimal dose and schedule.
Kobuchi S; Morita A; Jonan S; Amagase K; Ito Y
Cancer Chemother Pharmacol; 2024 Apr; 93(4):365-379. PubMed ID: 38117301
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle albumin-bound-paclitaxel: a limited improvement under the current therapeutic paradigm of pancreatic cancer.
Hoffman RM; Bouvet M
Expert Opin Pharmacother; 2015 May; 16(7):943-7. PubMed ID: 25887245
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus
Tajima H; Makino I; Gabata R; Okazaki M; Ohbatake Y; Shimbashi H; Nakanuma S; Saitoh H; Shimada M; Yamaguchi T; Okamoto K; Moriyama H; Kinoshita J; Nakamura K; Miyashita T; Ninomiya I; Fushida S; Ikeda H; Ohta T
Mol Clin Oncol; 2021 Feb; 14(2):26. PubMed ID: 33414907
[TBL] [Abstract][Full Text] [Related]
15. Prospective validation of patient fatigue questionnaire (FACIT-F) for fatigue assessment in nab-paclitaxel plus gemcitabine therapy.
Okada KI; Hirono S; Kawai M; Miyazawa M; Shimizu A; Kitahata Y; Ueno M; Hayami S; Shimokawa T; Yamaue H
Mol Clin Oncol; 2018 Jan; 8(1):121-126. PubMed ID: 29387403
[TBL] [Abstract][Full Text] [Related]
16. Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer.
Rich TA; Winter K; Safran H; Hoffman JP; Erickson B; Anne PR; Myerson RJ; Cline-Burkhardt VJ; Perez K; Willett C
Onco Targets Ther; 2012; 5():161-70. PubMed ID: 22977306
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of unresectable gallbladder cancer with low-dose paclitaxel as palliative chemotherapy after failure of gemcitabine and oral S-1: A case report.
Tajima H; Ohta T; Shinbashi H; Hirose A; Tsukada T; Okamoto K; Nakanuma S; Sakai S; Furukawa H; Makino I; Nakamura K; Hayashi H; Oyama K; Inokuchi M; Nakagawara H; Miyashita T; Fujita H; Takamura H; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Mouri H; Ohtsubo K
Oncol Lett; 2012 Dec; 4(6):1281-1284. PubMed ID: 23226802
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of neoadjuvant chemotherapy with gemcitabine plus oral S-1 for resectable pancreatic cancer.
Tajima H; Kitagawa H; Tsukada T; Nakanuma S; Okamoto K; Sakai S; Makino I; Furukawa H; Nakamura K; Hayashi H; Oyama K; Inokuchi M; Nakagawara H; Miyashita T; Fujita H; Itoh H; Takamura H; Ninomiya I; Fushida S; Fujimura T; Ohta T
Mol Clin Oncol; 2013 Jul; 1(4):768-772. PubMed ID: 24649244
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous triple cancer of the esophagus, pancreas and rectum treated with multimodal strategies: a case report.
Imamura H; Hirose H; Endo S; Hashimoto Y; Takeda M; Kidogami S; Mokutani Y; Kishimoto T; Yoshioka S; Tamura S; Sasaki Y
Surg Case Rep; 2020 Oct; 6(1):259. PubMed ID: 33006693
[TBL] [Abstract][Full Text] [Related]
20. Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer.
Shatsky RA; Batra-Sharma H; Helsten T; Schwab RB; Pittman EI; Pu M; Weihe E; Ghia EM; Rassenti LZ; Molinolo A; Cabrera B; Breitmeyer JB; Widhopf Ii GF; Messer K; Jamieson C; Kipps TJ; Parker BA
Breast Cancer Res; 2024 Mar; 26(1):46. PubMed ID: 38481291
[No Abstract] [Full Text] [Related]
[Next] [New Search]
